Trials / Completed
CompletedNCT00718731
Study GSI-136 in Healthy Young and Healthy Elderly Subjects
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSI 136 Administered Orally to Healthy Young and Healthy Elderly Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is a first-in-humans study of GSI-136, a drug being developed for the treatment of Alzheimer Disease. The main purpose of this study is to determine whether GSI-136 is safe and tolerable in healthy young and healthy elderly subjects. The amount of drug in the body and the effects of the drug on the body will also be evaluated at certain timepoints.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSI-136 | |
| OTHER | Placebo |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2008-07-21
- Last updated
- 2010-04-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00718731. Inclusion in this directory is not an endorsement.